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Abstract
Purpose: Early studies of chemotherapy in malignant glioma showed a small but 
significant benefit in survival with BCNU. VM26 had shown activity in malignant 
gliomas despite it’s low rate in passing the BBB. Several prognostic factors (PF) had 
been evaluated, but no criteria for adjusting therapy to these factors were established. 
Therefore a phase III study VM 26 in addition to BCNU in malignant glioma with 
special respect to interaction of therapy and prognostic factors was initiated.
Patients and methods: 
Malignant supratentorial glioma (anaplastic astrocytoma, oligoastrocytoma, 
oligodendroglioma and glioblastoma incl. gliosarcoma), age 16-70y, KPS 50-100. 
Postoperative randomization to chemotherapy with either BCNU (B) (80 mg/m2 x 3 
every 6 weeks) alone or additional VM 26 (V) (50 mg/m2 x 3 every 6 weeks) starting 
concomitant with radiotherapy. Central histopathological review was required. 
Primary endpoints were survival time (ST) and progression free survival (PFS) . In 
addition confirmative analysis of prognostic factors and their interaction with therapy 
was performed.
Results:
Eligible: 501 of 522 randomized pts: 82%  WHO grade IV gliomas, 18% grade III 
gliomas. 57% male, mean KPS 74, mean age 50.9 years. 
The high incidence of lung toxicity – with a cumulative risk of 19% during the first 
year - was alarming. Survival was not significantly different ( median 50.3 (B) versus 
52.4  (V) (weeks), but an increase in long term survivors was observed (18 months: 
29% B, 34% V, 5 years 5% B, 12% V) and PFS showed a significant difference with 
a median of 31.4 (B) versus 34.3 (V) weeks. Qualitative interaction between KPS and 
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therapy (p < 0.01) was demonstrated: pts with a KPS ≥ 70 benefited from additional 
VM26, those with reduced KPS < 70 did better with BCNU-monotherapy. 
Conclusion:
Adding VM26 to BCNU is effective in the chemotherapy of malignant gliomas. 
Because of the demonstrated interaction with therapy performance status, not  tumor 
grade is the crucial factor to determine application and aggressiveness of 
chemotherapy. With risk adapted therapy a significant proportion of patients even 
with glioblastoma survive for years in good general condition. BCNU should be 
replaced by an equipotent alkylans to avoid the unacceptable high rate of lung 
toxicity.
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Introduction
At the time of the design of this study results of  the first randomized trials of the 
Northamerican “Brain Tumor Study Group” (Walker et al. 1978, 1980) postoperative 
adjuvant radiochemotherapy with 60 Gray + BCNU as treatment of choice for 
malignant gliomas. No large European trial had been completed although several 
studies had been conducted by the EORTC Brain Tumour Group and in Italy and 
Hungary. So we set out for a randomized two arm-multi-center trial large enough to 
detect a difference in survival time of as low as 28% and particularly to allow for a 
reliable multivariate analysis of confounding factors. We asked the principal question 
if a combined chemotherapy is superior to mono-chemotherapy and whether various 
prognostic parameters influence the response to therapy. 
Because of the already known long term toxicity of standard whole brain irradiation 
we developed a protocol for regional radiation treatment by reducing the whole brain 
dose to 40 Gray. Regarding toxicity, a previous phase II study with serious pulmonary 
problems after BCNU and bleomycine in Würzburg had alerted us to demand a strict 
monitoring of the pulmonary function of our patients.
The ideal drug we looked for to add to the “gold standard” BCNU we found in 
VM26:efficant in phase 2 studies (19,45), particularly encouraging results in the 
study of Kessinger et al. (24). A phase 3 study of the EORTC in malignant gliomas 
showed in a randomised comparison of CCNU with CCNU + VM 26 an 8 week 
longer median survival for the combination but was underpowered to render this 
result statistically significant (22).
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Advantages of VM 26 were:
-   low hematotoxicity (in order to be able to give the full BCNU dose)
-  no known pulmonary toxicity 
-   no or only mild peripheral neurotoxicity
-   ability to pass the blood-CSF-barrier at least in patients after surgery and 
radiotherapy.
The dose we used was taken from the above mentioned EORTC trial in which no 
additional toxicity of VM26 to CCNU except rare allergic reactions was described. 
Our experience with some pilot patients of the combination of BCNU+VM26 was the 
same but we felt it necessary to monitor pulmonary function because no detailed data 
for this combination was available.
Patients and methods
522 patients were enrolled at 18 clinical centres in Germany and Austria between 
1983 and 1988. According to the study protocol follow-up had to be at least 2 years. 
Therefore the study was closed and finally analysed by the end of the year 1990. 
Eligibility
Criteria for enrollment:
- biopsy proven supratentorial malignant glioma / WHO grades III or IV: anaplastic 
astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma or 
glioblastoma – including gliosarcoma
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- Age 16 to 70 years
- Karnofsky performance score ≥ 50 at randomization (day 14-28 after resection / 
biopsy)
- No prior brain irradiation, no prior chemotherapy
- No other severe disease or contraindication for radio- or chemotherapy
- Documented consent by the informed patient
Trial design
14 – 28 days after surgery or biopsy, patients were randomized to either radiotherapy 
plus BCNU alone (B) or to radiotherapy plus BCNU and VM 26 (V). Primary 
endpoints of the study were survival and progression free survival.
Another main issue was the confirmative analysis of the predefined prognostic factors 
(PF) and their interaction with therapy.
Definitions
Survival time was measured from the time of surgery until death, censoring data at the 
date last seen for patients alive.
Progression / Relapse:
Progressive tumor in the CT scan anddeterioration of Karnofsky scale by 20 % or a 
50 % increase in the steroid dose.
Progression free survival:
Since many patients died after an only short final period of clinical deterioration, a 
significant group with clinically evident progression did not meet these progression 
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criteria. Therefore time to documented progression or death was defined as 
progression free survival.
Therapy
Surgery
Either resection or biopsy was required for inclusion. Macroscopic tumor resection 
was carried out whenever possible. The extent of the resection was estimated by the 
neurosurgeon. 
Chemotherapy
Chemotherapy started at the day of randomization , usually concomitant with 
radiotherapy. BCNU was administered at a dose of 80mg/m² at days 1-3 intravenously 
in a 20 min. infusion of 250 ml Glucose 5% . 
VM26: was administered at a dose of 50mg/m² at day 1-2 intravenously in a 20 min. 
infusion of 250 ml 0.9% NaCl immediately after BCNU for patients in group V.
Drugs were to be administered after every six weeks, if the blood count had recovered 
to at least 4 .0 G /l leucocytes and 100 G/l platelets, otherwise the interval was 
prolonged. The chemotherapy was continued until CR was achieved or progression 
was stated. In case of CR at least 2 consolidating cycles were prescribed. If there was 
no tumor rest after surgery or radiotherapy , chemotherapy had to be continued for 
one year after surgery. 
 Dose reduction to 75 % was mandatory if leukocytes dropped below 1,5G/l or 
platelets below 50G/l.
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Radiotherapy
Radiotherapy started simultaneously with the first cycle of chemotherapy 2-4 weeks 
after surgery. It was applied as high-voltage-energy (Photons or Cobalt 60) technique 
with 2 Gy 5 x weekly. After 40 Gy to the whole brain a recovery period of 5-10 days 
was scheduled. Radiation continued with a boost of 20 Gy (10 x 2Gy, 80% isodose) 
directed to the tumor area in the preoperative CT-scan including a 2 cm safety margin. 
The total tumor dose was 60 Gy.
Evaluation
Clinical examination and documentation
Before surgery, at randomization and every six weeks:
Neurological symptoms and signs using a detailed standard form, Karnofsky score, 
overall clinical state, dose of steroids, need of diuretics and antiepileptic drugs, overall 
assessment (remission / progression) – including CT results
Laboratory tests
Lung function testing before every application of chemotherapy
Weekly blood counts during chemotherapy, routine clinical chemistry monitoring 
before every cycle.
CT-Scan
Before surgery, at randomization, every three months during follow-up with and 
without contrast medium
CT findings were recorded on a standard form and rated independently without 
knowledge of the clinical course. 
Biometric assessment
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The sample size of 500 patients was calculated to detect a difference of 28% in 
survival time with an error level of α = 0.05 and β = 0.20. 
Survival time and time to progression were estimated using the Kaplan-Meier method, 
and compared with the Log-Rank test. Distributions of patient characteristics, side 
effects etc. were analyzed with contingence tables.
Randomization was performed stratified by centers. The effects of all other potential 
confounding variables were adjusted using the Cox proportional hazards regression 
model. The PF analysed were – age, sex, histological grading, Karnofsky status, 
extent of surgery, sex, duration of symptoms, organic brain syndrome, disturbed 
consciousness, concomitant disease, aphasia, seizures, need for antiepileptics and 
steroids, residual tumor.
All primary analyses were performed as „intention to treat“ evaluation. To monitor 
the effect of central histopathological diagnosis and of the applied therapy, some 
calculations were also done for the group of 443 patients with central reviewed 
pathology only. Since these did not differ from the analyses including all 501 patients, 
for further calculations the whole study group was used.
As one of the major goals of this study included an evaluation of prognostic factors 
and their interaction with therapy, the multivariate analysis with the Cox proportional 
hazard model (Cox 1972) was adapted to this topic. In this model „therapy“ is a 
covariate like the PF. But this covariate is the only factor, which is not a fateful trait 
of the patient, but can be modified. Thus, therapy is more important than the other 
covariates and needs special consideration. Therefore, the selection process of 
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variables for the Cox model has to keep track of “therapy” and its interaction with the 
prognostic factors even if the main effect of therapy on outcome seems to be weaker 
than other known PFs.
Using a three step backward stepwise selection the process started with the predefined 
13 prognostic factors, “therapy” and all interaction terms PF x “therapy”. To avoid 
artifacts, the significance level of the interaction terms was less (p < 0.01) than for the 
main effects (p < 0.05). Finally a Bonferroni-Holm procedure was applied to adjust 
for multiplicity of tested hypotheses. Ulm and Schmoor published the details of the 
procedure 1989 and 1993 .
Neuropathological Review
A primary histopathological diagnosis was established by the local pathologists / 
neuropathologists. The slides and paraffine blocks were reviewed by the Brain Tumor 
Reference Center of the German Society for Neuropathology and Neuroanatomy in 
Zürich.
WHO classification and grading criteria were applied (Zülch 1979). In addition, 
glioblastomas were separated into two distinct groups: Anaplastic gliomas with 
features of a WHO grade III but additional focal tumor necrosis were compared to 
tumors with full blown glioblastoma phenotype.
Results
55% of the 522 patients were randomized in three of the 18 clinical centers. Six of the 
centers entered less than 10 patients. 
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All randomized patients were included in the final analysis with the only exception of 
those 12 in which central pathological review revealed different tumor entities, e.g. 
metastasis, ependymoma, meningioma or low grade glioma.58 cases were classified 
according to the local pathologist since reference pathology was not available or not 
possible (in several cases with stereotactic biopsy only).
For 9 patients data were completely missing. 
So a total of 501 out of the original series of 522 randomized patients were eligible. 
Patient characteristics
Of the 501 eligible patients, 287 (57 %) were male, mean age was 52 years. Median 
KPS was 80 %.  
For 443 patients central histological review was available (i.e. 88% of all patients 
enrolled), with 18 % WHO grade III gliomas and 82 % glioblastomas WHO grade IV 
– including 12 % with features of of anaplastic glioma but focal necrosis. 6 % had no 
resection but biopsy only. During the course of the study, local pathologists appeared 
to adopt the criteria used by the central neuropathological review. The rate of 26% 
discrepancy in grading during the first three years dropped to only 16 % in the 
following period.
Clinical baseline parameters were documented at the day of randomization. Clinical 
data included: seizures, consciousness, EEG, papilledema, vomiting, Babinski’s sign, 
polyneuropathy, disorientation, aphasia, paresis (left/right, leg-arm), hemihypesthesia. 
Laboratory tests: blood counts, LDH, ALAT, urea, creatinine, alkaline phosphatase, 
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bilirubin.  For most of the parameters less than 5 % of the individual values were 
missing. Regarding all these parameters there were no differences between the 
treatment arms.
German-Austrian-Glioma-Study  B. Müller  14/30
Study treatment and adverse effects
Randomization, start of chemotherapy, and simultaneous start of radiation all were 
scheduled 14-28 days after surgery. Randomization was done at the biometric center 
in Munich by call. In rare cases due to acute deterioration the study therapy couldn’t 
start at all.
Radiotherapy
72 % of the patients received the scheduled radiotherapy. 15 (3%) did not receive 
radiotherapy at all and in 73 (15%) radiation was stopped mainly due to early 
deterioration with no differences between treatment or Karnofsky groups. In 45 cases, 
single fractions of 1.8 instead of 2 Gy were used, in 9 patients the relation of 
WBI/boost dosage varied. Overall, only few protocol violations occurred, most 
modifications occurred due to medical reasons. No differences in the applied 
radiotherapy were seen between the treatment groups.
Chemotherapy
Eight patients randomized to B and 10 randomized to V did not receive any 
chemotherapy. 92% of the patients received an initial dose of 75-85 mg/m²day for 
BCNU (no differences in B and V) arm, and 80% of the V-group a first dose of 45-55 
mg/m² VM 26. Reduced initial dosage was mainly due to acute side effects like steep 
fall of leucocytes or platelets, fever or allergic reactions. 
In average the dosage of the cycles had to be reduced by 10% of the standard dose . In 
11% after the 1st and 2nd cycle, 16 % after the 3rd , and in 20% after the 4th cycle. To 
reflect the relative cumulative dosage, the cumulated dose of BCNU in relation to the 
initial standard dose of 240mg/m² for the first cycle was calculated – in average the 
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BCNU dose of 3.4 standard cycles was applied. The V group (3.5 cycles) received a 
somewhat higher BCNU total dose than the B group (3.0 cycles), although no 
differences in treatment intervals and need for dose reduction were found. (Table 2)
Adverse effects
Hematotoxicity
No differences in hematotoxicity were seen between both treatment arms (Table 3). 
The overall hematotoxicity was tolerable. Severe toxicity mainly occurred in cases 
with inadequate hematological monitoring or delayed dose reduction. In 20 % of the 
patients nadirs of leucocytes less than 1.5 G/l or platelets less than 50 G/l were seen 
equally distributed in both arms.
Of the cycles the nadirs of leucocytes or platelets were less than 1.5 or 50 G/l 
respectively in 10% with the need of dose reduction for the further cycles.  In 30% of 
these cycles, i.e. 3% of all cycles, however, the doses were not according to the 
protocol correctly adapted.
Pulmonary toxicity
Although we had been alerted by pulmonary toxicity in our previous phase II study 
and in spite of the strict monitoring of pulmonary function, lung toxicity was the main 
hazard in this study. 
Lung function testing was done before every cycle of chemotherapy with a full 
pulmological evaluation by the Body-test with particular emphasis on the parameters 
of restriction and – where possible – on the CO-diffusion test which turned out to be 
the most sensitive method to diagnose a beginning pulmonary fibrosis. The diagnosis 
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of lung fibrosis was made if histologically proven or chest x-ray as well as lung 
function test and clinical symptoms according to pulmonological evaluation were 
characteristic for the disease. The data of table 4 refer to patients with characteristic 
lung function impairment in whom other possible reasons like infection or embolism 
were clinically excluded. That means that only well documented patients could be 
included and the real frequency of lung function impairment probably was still higher.
In contrast to the literature, there was no “threshold” dose of BCNU and we observed 
proven lung fibrosis after only one single cycle of BCNU. Even early discontinuation 
of BCNU treatment with asymptomatic deterioration of lung capacity did not prevent 
progressive lung fibrosis. In fact, some patients started with lung problems years after 
chemotherapy had been terminated. Table 4 shows the rate of documented 
symptomatic lung fibrosis. 
The calculated hazards of lung function disorder during the first two years were 
presented in figure 1.
In 17 of our patients death due to lung fibrosis had been proven, but the rate could be 
even higher, since sometimes acute interstitial pneumonitis may be misinterpreted as 
an infectious pneumonia.
Other adverse effects
A broad range of adverse events were routinely monitored, irrespectively whether 
they originated from the disease itself, from symptomatic or antineoplastic treatment. 
The hepatotoxicity was mainly due to antiepileptics (Table 5).
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Follow-Up
At completion of the trial 396 (79 %) of 501 patients had died, 197 (81 %) in the B 
and 199 (77%) in the V group. Causes of death were classified as 
- related to tumor
- general complication (lung embolism, infections not due to myelosuppression)
- specific complications of antineoplastic therapy (e.g. lung toxicity, 
hematotoxicity, infections in myelosuppression)
- unknown
- not related to tumor or therapy (e.g. trauma, not related to a fit) (Table 6)
The median follow-up period was more than 3 years. 105 patients were still alive at 
last follow-up, 73 of them had been documented for more than one year. Only 32 
patients (6%) - equally distributed to the treatment arms – had a follow-up of less than 
one year. 
Of the 501 patients disease progression was documented in 296 and 132 patients died 
without verified progression. In 73 patients neither progression nor death occurred 
with 18 documented for more than three years. 25 of them (5%) had an incomplete 
follow-up of less than one year and may be regarded as drop outs. For all other pats. 
full or sufficient data are available.
Survival and progression free survival
The Kaplan-Meier estimate of median survival time was 358 days. The difference 
between the survival curves (median: arm B 352 days, arm V 374 days) did not reach 
statistic significance (figure 2).
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However, progression free survival with an overall median of 230 days showed a 
statistically significant (p < 0.05) difference in the curves between arm B (median 220 
days) and arm V (median 240 days) compared by the Logrank test (see figure 2). . 
We used more rigid progression criteria than we have today with much better neuro-
imaging available. These criteria were deliberately defined to avoid declaration of 
pseudo-progressions after only slight changes in neuro-imaging or clinical status. 
Local definitions were monitored by central review. So we may have missed early or 
slight progressions. The diagnosis of a progression, however, was sound allowing for 
a more precise definition of the progression free interval. Patients were never taken 
off study but documented until death. Other therapies were not allowed unless 
progression or relapse was stated. CT-evaluations were done blinded for the clinical 
status. Procedures were identical in both arms and therefore bias in the definition of 
progression is highly unlikely, but cannot completely be excluded. So our more rigid 
progression criteria should have contributed to a more reliable result regarding the 
PFS.
There are many potential reasons that in contrast to the PFS there is no difference in 
overall survival. Among them is the high frequency of  toxic and slowly progressive 
and sometimes fatal lung impairment or a possible different treatment after relapse.
A small, but significant advantage for the combination chemotherapy with BCNU and 
VM 26 thus could be confirmed. The medians differ only slightly, but the difference 
between the curves appears to get more pronounced with longer follow-up. Since 
there are still many patients at risk even after 18 months (127 for ST, 75 for PFS), two 
years (65 for ST, 41 for PFS) and three years (29 for ST, 22 for PFS) this mainly 
contributes to the significant result, (Table 7).
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Prognostic factors and their interaction with therapy
As stated in the study protocol, evaluation of prognostic factors and their interaction 
with treatment was the second main goal of this trial.
When analyzing subgroups related to the predefined main prognostic variables, a 
qualitative interaction between Karnofsky score and therapy has to be assumed even 
after univariate comparison, (Table 8, Figure 3).
Histopathological grading evolved as the most important genuine prognostic factor in 
the trial. An additional analysis was performed for a subgroup of WHO grade IV 
tumors, meeting all criteria for a WHO grade III glioma but with focal necrosis 
qualifying for grade 4. This intermediate group showed no evidence for additional 
prognostic power compared to ordinary glioblastomas, indicating that necrosis in an 
anaplastic glioma justifies its classification as glioblastoma grade IV – at least for 
newly diagnosed tumors, in which no treatment effects after irradiation or 
chemotherapy are to be considered.
In spite of its strong prognostic impact, no qualitative interaction between tumor grade 
and therapy can be anticipated, (Figure 4).
The subtype of glioma plays a major prognostic role for prognosis as stated in 
numerous recent publications.
. This finding was confirmed here for the small set of grade III gliomas - showing a 
better survival in oligodendroglioma – (Figure 5)
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Prognostic differentiation can also be seen in the subgroup analysis for age groups, 
with a longer survival and greater effect of the combination treatment  in younger 
patients - but again there is no hint to a qualitative interaction with therapy. (Figure 6)
To find out an explanation for the interaction of the unspecific and general prognostic 
factor “Karnofsky status” with the kind of chemotherapy we looked at any aspect 
possibly differentiating the Karnofsky and/or chemotherapy groups we could analyse 
in our data. But we found no differences in any of the systematic documented side 
effects – especially no differences regarding hematotoxicity, lung fibrosis, acute 
emesis. Particularly therapy related deaths were not more frequent in patients with 
low KPS. Unspecific complications (e.g. thrombosis) were a little more frequent in 
the low KPS group – but not correlated to VM26. Higher KPS patients received more 
chemotherapy – but this is also due to the longer survival of the higher KPS patients. 
There is a small tendency of early discontinuation of therapy in low KPS patients.
The only “soft” aspect was found in the “free text remarks” – there were more general 
complaints about anorexia and “fatigue” in the VM26 group probably intensifying the 
reduced tolerance of the low Karnofsky group of the aggressive therapy. This item 
(during the interval) was not included in our standard forms and we were not able to 
analyse it in more detail.
Cox proportional hazards model
 
As described above, a three step backward selection procedure with special attention 
to therapy and their interaction generated the final set of covariates. 
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Since only patients with complete data for all the covariates can be included in a 
multivariate analysis, 437 patients with complete data of the supposed 14 PF were 
available for the multivariate analysis:
Age, sex, KPS, histological grade, extent of surgery, duration of symptoms, organic 
brain syndrome, disturbed consciousness, aphasia, concomitant disease, seizures, need 
of antiepileptics and steroids.
To confirm an interaction between prognostic factors and therapy, an adjusted Cox 
Model  was established. In a first step, all prognostic factors were analyzed for their 
impact on survival and their correlation with therapy. The interaction of KPS with 
therapy was highly significant. All other cross-terms, even of the prominent main 
factors age and histology did not yield significant interactions.
In a second step the remaining interaction of step one and the PF formed were 
combined. For the third step all PF neither showing interaction nor significant main 
effect were excluded. The definite model comprised age, histological grade, resection 
versus biopsy, type of resection, organic brain syndrome, disturbed consciousness, 
seizures, need of steroids (see Table 9)
To overcome the problem of multiple hypothesis testing, an adjustment of the 
significance level using the Bonferroni-Holm procedure (Holm 1979) was performed.
The overall result confirmed not only a quantitative but a qualitative interaction 
between the initial KPS and the treatment – confirming that patients with better KPS 
had significant benefit from additional VM 26, but patients with KPS < 70 did better 
with BCNU only. All other prognostic factors, although significant, showed no 
relevant interaction with therapy. Main individual factors were age and histology, but 
extent of surgery and the need of steroids also showed a prognostic impact. 
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This finding could be confirmed in a bootstrap resampling procedure, applying the 
Cox model repetitively 100 times to randomly selected sets of the original data. These 
variations reproduced the interaction of Karnofsky and therapy in 97 %  (Figure 7).
Discussion
Overall result:
Our study demonstrates an advantage of the combination chemotherapy compared to 
standard BCNU monotherapy in terms of progression free survival and long term 
survivors. The effect was only small, indeed, and regarding median survival it was not 
statistically significant. Median survival was in the upperrange of other phase III trials 
of combined chemo- and radiotherapy for newly diagnosed malignant glioma with 
comparable patient populations (NOA2003, Stupp2004, see also Table 10) and is 
concordant with the meta-analysis of 12 randomised trials with 3004 patients (Stewart 
2002).
We identified a high incidence of severe lung toxicity not yet reported in other BCNU 
trials and compromising the survival of our patients. This finding was possibly due to 
a systematic monitoring of pulmonary functions and the special attention we paid to 
this problem, particularly after our first case of lethal acute interstitial pneumonitis 
after the second BCNU course, which was verified as lung fibrosis by autopsy. Acute 
toxic interstitial pneumonitis is easily misinterpreted as an infectious pneumonia but 
must be considered in any acute failure of oxygenation without inflammatory reaction 
. 
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Many cases progressed to full blown lung fibrosis even after aborting chemotherapy 
early in contrast to the theory of a threshold dose of approx. 1500mg BCNU reported 
by Aronin  and Weinstein, . The true incidence of this variant of pulmonary toxicity 
can be only detected with long-term follow-up. It is easily underestimated in clinical 
trials monitoring only acute toxicity .
Interaction of chemotherapy and Karnofsky
The main result of this trial is the proof of a qualitative interaction of therapy and the 
overall performance status (Karnofsky score). Detailed analysis of side effects, 
hematological and pulmonary toxicity, clinical symptoms, concomitant diseases did 
not reveal any more specific factor.
Although there was a slight tendency to early discontinuation of therapy in the low 
performance group, there were no overt differences in tolerability. In particular the 
addition of VM26 did not contribute to early discontinuation.
PF had been evaluated in most of the phase III studies in malignant gliomas, and in 
addition in several meta-analyses . Most studies show the predictive value of the PFs 
for survival and try to identify patients with better results of the tested therapy by 
analyzing multiple subgroups , sometimes additionally tailored by further conditions 
such as “response” or „adequate treatment“ . 
The error of testing multiple hypotheses and bias by selection after randomization 
curtail the reliability of such findings, which only should be used for exploration and 
generation of new hypotheses, requiring confirmation in an independent population. 
This is particularly true for the recently popular CART or recursive partitioning 
analyses .
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In addition, a valid correlation between different PFs and of a given PF with therapy 
can only be established in a multivariate analysis – such as the Cox proportional 
hazards model. Until now, multivariate procedures were mostly used to confirm the 
relative weight of the covariates – PFs and therapy -  and to give a confident 
estimation of prognosis in heterogeneous subgroups . Further statistical modeling was 
necessary to confirm also the interaction with therapy (see  for details).
Conclusion:
As a main consequence of this trial, chemotherapy in malignant glioma mainly should 
be adjusted to KPS, since histology and age don’t show relevant interaction with 
therapy. For patients with less favorable condition avoiding toxicity is crucial and 
individually tailored, possibly less intensive regimens may be more appropriate. 
Furthermore the frequent and severe pulmonary toxicity of BCNU raises concern 
regarding further use of BCNU in brain tumors, since obviously less toxic and at least 
as efficient chemotherapeutic agents like ACNU or temozolomide (NOA2003, 
Stupp2004) are available. 
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Parameters
B
N = 242
V
N = 259
All
N = 501
Age
median 54 years 55 years 54 years
Sex
male:female 57% : 43% 57% : 43% 287:214
Duration of symptoms
 median 6 weeks 6 weeks 6 weeks
Surgery
Biopsy
Resection:
partial (10-90 %)
subtotal (> 90 %)
total
other
missing
11 %
25 %
30 %
33 %
0
5
6 %
27 %
32 %
34 %
2
6
9%
26 %
31 %
34 %
2
11
Histology, local
grade 3
grade 4
unspecified, malignant
24 %
61 %
15 %
25 %
63 %
12 %
24 %
62 %
14 %
Histology, review
grade 3
grade 4
missing
18 %
82 %
29
19 %
81 %
29
18 %
82 %
58
Karnofsky
50
60
70
80
90
100
13 %
15 %
21 %
27 %
19 %
6 %
12 %
16 %
21 %
25 %
21 %
4 %
12 %
15 %
21 %
26 %
20 %
5 %
Concomitant disease 14 % 15 % 15 %
Seizures
none
focal
generalized
68 %
17 %
15 %
69 %
15 %
16 %
69 %
15 %
16 %
Organic brain syndrome
none
mild
moderate
severe
44 %
33 %
19 %
4 %
42 %
33 %
17 %
8 %
43 %
33 %
18 %
6 %
Aphasia 28 % 27 % 27 %
Reduced vigilance 22 % 23 % 23 %
Antiepileptics 71 % 69 % 70
Steroids 68 % 64 % 66 %
Table 1:  Distribution of  baseline characteristics for B, V, all patients
Chemotherapy B
N = 242
V
N = 259
All
N = 501
Cycles
Median
mean ± SD
3
3.48 ± 2.32
3
3.66± 2.46
3
3.55 ± 2.41
BCNU dose – cumulated
total (mean ± SD)
total / Standard*
1344 mg ± 1014
3.01
1553 mg ± 1079
3.48
1498mg  ± 1060
3.37
Interval 1st – 2nd cycle
– 45 days
46 – 50 days
51 – 60 days
> 60 days
43 %
15 %
19 %
24 %
42 %
23 %
12 %
23 %
43 %
19 %
15 %
23 %
*Standard: 240 mg BCNU / m2 – dose of a regular cycle
Table 2: Applied chemotherapy for B,V and all patients
Parameter B V
Hemoglobin
> 10 g/dl
8 -< 10 g/dl
< 8 g/dl
89 %
11 %
0,3%
90%
9 %
2 %
Leukocytes
> 3G/l
(2 – 3] G/l
(1- 2] G/l
(0.5-1] G/l
< 0.5 G/l
58 %
25 %
14 %
2 %
1 %
63 %
23 %
11 %
3 %
0,4 %
Platelets
> 100 G/l
(50 – 100] G/l
 (25 – 50] G/l
< 25 G/l
73 %
16 %
8 %
3 %
74 %
18 %
6 %
3 %
Table 3: Nadirs of Hemoglobin, leucocytes and platelets in % of applied cycles
Lung fibrosis B
n = 242
V
n = 259
≥ grade 1
≥ grade 2
grade 3
19 %
11 %
6 %
17 %
12 %
4 %
Table 4: Rate of restrictive lung disease during first year
grade 1: symptoms only during heavy physical activity
grade 2: symptoms during normal activity
grade 3: symptoms at rest
B V
Adverse effect: 964 cycles 1048 cycles
Infection
Hemorrhage
Renal toxicity
Hepatotoxicity
Gastroinstestinal sympt.
Nausea and vomiting
Other
3.9 %
1.1 %
0 %
5.3 %
0.9 %
4.8 %
6.7 %
3.9 %
0.7 %
0 %
5.2 %
1.5 %
8.4 %
8.3 %
Table 5: Adverse effects in % of applied cycles
Causes of death B
N = 242
V
N = 259
All
N = 501
dead 197 (81%) 199 (77%) 396   (79%)
(100%)
Related to tumor
Other reasons
including:
155
42
171
28
326  (83%)
70   (17%)
General complication
- lung embolism
26
11
12
7
38  (10%)
18     (5%)
Specific complication
- lung toxicity
- hematotoxicity
12
6
5
13
11
1
25    (6%)
17 (4%)
6
Unknown 3 3 6
Not related to tumor or
therapy
1 1 2
Table 6: Causes of death (for definitions see text)
B
N = 242
V
N = 259
All
N = 501
Survival
Median
18 months
2 years
3 years
352 days
29 %
15 %
5 %
374 days
34 %
22 %
15 %
358 days
31 %
19 %
13 %
Progression free survival
Median
18 months
2 years
3 years
220 days
14 %
9 %
6 %
240 days
22 %
14 %
11 %
230 days
18 %
12 %
9 %
Table 7: Long-term results (survival and progression free survival)
B V All
N mST N mST N mST
Whole group 242 352 259 374 501 358
Age
≤ 50 y.
> 50 y.
96
146
449
302
87
172
584
303
183
318
502
302
Grading
WHO grade III
WHO grade IV
43
174
758
320
47
204
717
331
90
396
717
324
Karnofsky
< 70
≥ 70
67
175
322
360
74
185
198
468
141
360
256
425
Surgery
biopsy
partial/subtotal
total
27
130
79
207
323
405
15
149
87
141
394
428
42
279
166
159
358
424
Table 8: Median survival time (days) in subgroups defined by prognostic factors and
therapy

Step 1 Step 2 Step 3
PF x therapy main effect Final model
Factor Х2 Х2 Coeff/SE
Age 0.35 51.51  * 6.68
Sex 1.11 1.06
Karnofsky      14.86  **       0.66 ***
Histological grading 0.63 34.89  * 5.80
Surgery – total vs non total
Biopsy vs surgery
0.74
0.96
5.44  *
14.12  *
-2.28
4.08
Duration of symptoms 1.2 1.06
Organic brain syndrome 0.38 5.53  * -2.17
Reduced vigilance 0.39 4.61  * -2.31
Aphasia 1.81 0.27
Concomitant disease 4.53 0.94
Seizures 0.81 6.04 -2.46
Antiepileptics 0.97 0.04
Steroids 0.30     9.17  * 2.86
Karnofsky
„ x therapy 29.12  *
Therapy
„ x Karnofsky 19.76  *
Karnofsky x therapy -4.28***
Therapy        2.72***
*** the numbers for KPS and therapy can’t be compared with the other PF,
but must be interpreted together with the interaction
** p < 0.01, interaction term selected for step 2
* p < 0.05, variate selected for step 3
Table 9: Multivariate analysis of prognostic factors and their interaction with therapy
with an adjusted Cox proportional hazards model

Therapy: radiotherapy + n (e/r) % GB Age  % Bps m-ST % 18m Ref.
BCNU 80mg/m² d1-3/6w 166/185 81 56 0 57 29 {{Shapiro1989}}
BCNU 80mg/m² d1-3/8w 140/152 87 58 0 43 16 {{Deutsch1989}}
BCNU 200mg/m² d1 /7w 1st /10w 2nd y. 166/172 72 59 21 48 30 {{Dinapoli1993}}
BCNU 200mg/m² d1 /7w 114/117 60 61 11 41 27 {{Elliott1997}}
BCNU 80mg/m² d1-3/6w 242/253 82 54 11 50 29
CCNU 100mg/m² d1/6w 94/? 41 47 ? 52 ? {{TROJANOWSKI1988}}
ACNU 100mg/m² - d1 +d40 40/57 65 50 ? 60 ? {{TAKAKURA1986}}
PCNU 100mg/m² d1 /7w 1st /10w 2nd y. 168/174 70 58 18 47 25 {{Dinapoli1993}}
PCZ  150mg/m²/d1-d28/8w 128/153 89 56 ? 47 29 {{GREEN1983}}
DBD 200mg/m² d1-10 /5w p.o. 115/121 56 59 13 41 23 {{Elliott1997}}
BCNU  80mg/m²d1-3+
    PCZ 150mg/m² d56-84  p.o. /16w
176/196 79 56 0 49 32 {{SHAPIRO1989}}
BCNU  80mg/m² d1-3 +
    HU 1g/m² d2-22 p.o. +
    PCZ 150mg/m² d56-84 p.o.
    VM26 130mg/m² d56,63,70,77,84,91 /16w
168/190 79 57 0 60 37 {{SHAPIRO1989}}
BCNU  80mg/m² d1-3+
    VM26 50mg/m² d2-3 /6w
259/268 81 55 6 53 34
DBD 700mg/m² d1,8,15,22,29,36 during RT
DBD 1000mg/m² d1 +
    BCNU 150mg/m² d2 /6w
127/135 79 54 8 58 {{HILDEBRAND1994}}
PCZ 100mg/m² d1-10,
CCNU 100mg/m² d1 +
    VCR 1.5mg/m² d1 /6w
327/335 67 54 42 43 about 23 {{BTG 2001}}
Radiotherapy 55-60 Gy tumordose - WBI+Boost
n: number, e: eligible, r: randomized
% GB, % Bps: percentage of glioblastoma or biopsy only, resp.
m-ST: median survival time in weeks
% 18M: percentage alive at 18 months
Table 10: Adjuvant radio- and chemotherapy in newly diagnosed malignant gliomas (randomized studies)
BCNU+VM 26 233 198 154 121 96 73 58 46
BCNU 219 184 146 106 78 56 37 30
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Figure 2: Kaplan-Meier curves for survival and progression free survival. The difference is significant for PFS
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Figure 3: Kaplan-Meier survival curves for the Karnofsky groups <70 and 70-100 and therapy – showing an inverse effect of additional
VM 26 in patients with good and reduced KPS
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Figure 4: Kaplan-Meier survival curves (months) for the grade III and IV tumors demonstrate the
strong impact on prognosis. There are no apparent differences between the histological subgroups
with respect to treatment effect.
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Figure 5: Kaplan-Meier survival curves (months) for anaplastic astrocytoma and anaplastic
oligodendroglioma – 5 year follow up
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Figure 6: Kaplan-Meier survival curves (months) for age groups demonstrate the high prognostic
importance of age but do not point to a qualitative interaction between age and therapy.
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Figure 7: Frequency (%) of selection in bootstrap resampling for the Cox Model {{Ulm1989}}
Left half shows the relative prognostic power of the single factors. Right half depicts how often a
factor was identified with relevant interaction with therapy in 100 randomly selected data sets.
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Figure 1: Estimated cumulated risk of symptomatic restrictive lung function disorder (Kaplan –
Meier, censoring tumor-related death)
